Guideline of Improvement and Evaluation of Prescribing Errors in Colorectal Chemotherapy

대장암 항암 화학요법의 처방 오류 평가 및 개선안 제시

  • Lim, Hyun-Soo (Department of Pharmacy, Chungbuk National University) ;
  • Lim, Sung Cil (Department of Pharmacy, Chungbuk National University)
  • 임현수 (충북대학교 약학대학 임상약학연구실) ;
  • 임성실 (충북대학교 약학대학 임상약학연구실)
  • Received : 2013.01.07
  • Accepted : 2013.04.22
  • Published : 2013.06.30

Abstract

Background: Colorectal cancer shows a significant increase in South Korea due to westernization of diet, lack of dietary fiber, drinking and smoking, irregular defecation. There are surgery, chemotherapy, radiation therapy in treatment of colorectal cancer. There may be a medication errors in the process of chemotherapy because of its high toxicity, narrow therapeutic index and the health status of cancer patients. Consequently medication errors can cause increasing the risk of death, prolonging hospital stay and increasing the cost. Among medication errors on medication use process, prescribing errors are of particular concern due to higher risk of serious consequences. It is important for pharmacist to prevent the prescribing errors before reaching patient. Therefore we analyzed the prescriptions of colorectal cancer, classified prescribing errors, suggested guideline to reduce prescribing errors and verified the importance of pharmacist's role in prevention of medication errors activity. Methods: We collected the numbers of prescriptions of colorectal cancer(n=2,373) through anti cancer management program and EMR and analyzed the errors of prescriptions by categories from Oct 1st 2011 to Sep 30th 2012 at Chungbuk National University Hospital. We reviewed the prescriptions as follows - patients' characteristics, the result of test, previous prescriptions, characteristics of antineoplastic agents and patients' allergy, drug sensitivity, adverse events. Prescriptions are classified into inpatient and outpatient and analyzed the errors of prescriptions by categories (dosage form, dose, input, diluents, regimen, product). Results: Total prescription number of inpatient and outpatient of colorectal cancer was 1,193 and 1,180 and that of errors was 107(9%) and 22(1.9%), respectively. In case of errors of categories, the number of errors of dosage form is 69 and 8, errors of dose is 15 and 5, errors of input is 9 and 9 in inpatient and outpatient prescriptions, respectively. Errors of diluents is 8, errors of regimen is 3, errors of product is 3 in only inpatient prescriptions. In case of errors of categories by inpatient department, the number of errors of dosage form is 34 and 35, errors of dose is 7 and 8, errors of input is 6 and 3, errors of diluents is 4 and 4, errors of regimen is 2 and 1, errors of product is 2 and 1 in SG and HO, respectively. In case of outpatient department, the number of errors of dosage form is 8 in HO, errors of dose is 5 in HO, errors of input is 5 and 4 in SG and HO, respectively. Conclusions: The rate of errors of inpatient is higher than that of outpatient. Junior doctors are engaged in prescriptions of inpatient and pharmacist need to pay attention to review all prescriptions. If prescribing errors are discovered, pharmacist should contact the prescriber and correct the errors without delay. The guideline to reduce prescribing errors might be upgrading software of anti cancer management program, education for physicians as well as pharmacists and calling prescriber's attention to preventing recurrence of errors.

Keywords

References

  1. National Cancer Information Center. http://www.cancer.go.kr/
  2. Koh SJ, Kim JS, The Reasons for the Increased Incidence of Colorectal Cancer in Korea. The Korean J of Medicine 2010; 79(2): 97-103.
  3. Kim YT, .Lee HR, Lee OY, et al., Young Aged Colorectal Cancer Patients: Do They Have a Bad Prognosis?. Korean J Gastrointest Endosc, 2010; 40: 84-9.
  4. Greenwald B. The Emergency of Technology in Colorectal Cancer Screening. Gastroentolol Nurs 2005; 28: 90-6. https://doi.org/10.1097/00001610-200503000-00002
  5. Sung JJ, Lau JY, Goh KL, et al., Increasing Incidence of Colorecal Cancer in Asia: Implication for Screening. Lancet Oncol 2005; 6: 871-6. https://doi.org/10.1016/S1470-2045(05)70422-8
  6. Cho SH. Adjuvant Chemotherapy in Colon Cancer. The Korean J Med 2012; 83(3): 297-304. https://doi.org/10.3904/kjm.2012.83.3.297
  7. Beatty GL, Bruce JG. Bevacizumab and Oxaliplatin-based Chemotherapy in Metastatic Colorectal Cancer. Expert Review of Anticancer therapy 2008; 8(5): 683-8. https://doi.org/10.1586/14737140.8.5.683
  8. Slama CJ. Jerome C. Jacquot BB. Prescription Errors with Cytotoxic Drugs and Inadequacy of Existing Classifications, Pharm World Sci 2005; 27: 339-43. https://doi.org/10.1007/s11096-005-6034-x
  9. Ranchon F, Salles G, Spath H, et al., Chemotherapeutic Errors in Hospitalized Cancer Patients: Attributable Damage and Extra Costs, BMC Cancer 2011; 11: 478-7. https://doi.org/10.1186/1471-2407-11-478
  10. Schulmeister L. Chemotherapy Medication Errors: Description, Severity, and Contributing Factors. Oncol Nurs Forum 1999; 26(6): 1033-42.
  11. Classen DC, Pestotnik SL, Evans RS. Adverse Drug Events in Hospitalized Patients. Excess Length of Stay, Extra Costs and Attributable Mortality, JAMA 1997; 277: 301-6. https://doi.org/10.1001/jama.1997.03540280039031
  12. Lustig A. Medication Error Prevention by Pharmacists-An Israeli Solution. Pharmacy World & Science 2000; 22(1): 21-5. https://doi.org/10.1023/A:1008774206261
  13. Serrano-Fabia A, Albert-Mari A, Almenar-Cubells D, et al., Multidisciplinary System for Detecting Medication Errors in Antineoplastic Chemotherapy. J Oncol Parm Practice 2010; 16: 105-12. https://doi.org/10.1177/1078155209340482
  14. Lesar TS, Briceland L, Stein DS. Factors Related to Errors in Medication Prescribing. JAMA 1997; 277: 301-6. https://doi.org/10.1001/jama.1997.03540280039031
  15. Dean B, Schachter M, Vincent C, et al., Causes of Prescribing Errors in Hospital Inpatients: a Prospective Study. Lancet 2002; 359(9315): 1373-8. https://doi.org/10.1016/S0140-6736(02)08350-2
  16. Beckwith MC, Tyler LS. Preventing Medication Errors with Antineoplastic Agents. Part I, Hosp Pharm 2002; 35: 511-25.
  17. Leape LL, Bates DW, Cullen DJ. System Analysis of Adverse Drug Events. JAMA 1995; 274: 35-43. https://doi.org/10.1001/jama.1995.03530010049034
  18. Bates DW, Cullen DJ, Laird N, et al., Incidence of Adverse Drug Events and Potential Adverse Drug Events. Implications for Prevention, ADE Prevention Study Group. JAMA 1995; 274(1): 29-34. https://doi.org/10.1001/jama.1995.03530010043033
  19. Abdel-Qader DH, Harper L, Cantrill JA, et al., Pharmacists' Interventions in Prescribing Errors at Hospital Discharge. Drug Saf 2010; 33(11): 1027-44. https://doi.org/10.2165/11538310-000000000-00000
  20. Donyai, P, O'Grady K, Jacklin A, et al., The Effects of Electronic Prescribing on the Quality of Prescribing. Br J Clin Pharmacol 2008; 65(2): 230-7. https://doi.org/10.1111/j.1365-2125.2007.02995.x
  21. Devine EB, Wilson-Norton JL, Lawless NM, et al., Characterization of Prescribing Errors in an Internal Medicine Clinic. Am J Health Syst Pharm 2007; 64(10): 1062-70. https://doi.org/10.2146/ajhp060125
  22. ASHP Council on Professional Affairs, ASHP Board of Directors, ASHP Guidelines on Preventing Medication Errors with Antineoplastic Agents. Am J Health-Syst Pharm 2002; 59: 1648-68.
  23. Tully MP, Buchan LE. Prescribing Errors during Hospital Inpatient Care: Factors Influencing Identification by Pharmacists. Pharm World Sci 2009; 31: 682-8. https://doi.org/10.1007/s11096-009-9332-x
  24. Ministry of Health & Welfare. http://www.mw.go.kr/
  25. Ruder AD, Smith DL, Madsen MT, et al., Is There a Benefit to Having a Clinical Oncology Pharmacist on Staff at a Community Oncology Clinic? J of Oncol Pharm Practice 2010; 17(4): 425-32.